Document Detail

Altered local and systemic immune profiles underlie lymph node metastasis in breast cancer patients.
MedLine Citation:
PMID:  23136075     Owner:  NLM     Status:  Publisher    
Cancer-mediated immune dysfunction contributes to tumor progression and correlates with patient outcome. Metastasis to tumor draining lymph nodes (TDLNs) is an important step in breast cancer progression and is used to predict patient outcome and survival. While lymph nodes are important immune organs, the role of immune cells in TDLNs has not been thoroughly investigated. We hypothesized that the host immune response in node negative (NN) patients is more intact and thereby can resist tumor invasion compared to node positive (NP) patients. As such, lymph node metastasis requires breakdown of the host immune response in addition to escape of cancer cells from the tumor. To investigate the immunological differences between NN and NP breast cancer patients, we purified and profiled immune cells from the three major compartments where cancer and immune cells interact: tumor, TDLNs, and peripheral blood. Significant down-regulation of genes associated with immune-related pathways and up-regulation of genes associated with tumor-promoting pathways was consistently observed in NP patients' TDLNs compared to NN patients. Importantly, these signatures were seen even in NP patients' tumor-free TDLNs, suggesting that such immune changes are not driven solely by local tumor invasion. Furthermore, similar patterns were also observed in NP patients' tumor and blood immune cells, suggesting that immunological differences between NN and NP patients are systemic. Together, these findings suggest that alterations in overall immune function may underlie risk for LN metastasis in breast cancer patients. © 2012 Wiley Periodicals, Inc.
Neta S Zuckerman; Hongxiang Yu; Diana L Simons; Nupur Bhattacharya; Valeria Carcamo-Cavazos; Ning Yan; Frederick M Dirbas; Denise L Johnson; Erich J Schwartz; Peter P Lee
Related Documents :
12060635 - Adenoviral-mediated expression of mmac/pten inhibits proliferation and metastasis of hu...
17998805 - Dominant-negative hif-3 alpha 4 suppresses vhl-null renal cell carcinoma progression.
23946775 - Expression and clinical significance of complement c3, complement c4b1 and apolipoprote...
14608035 - Haploinsufficiency of anx7 tumor suppressor gene and consequent genomic instability pro...
23451905 - Retrospective analysis of the tolerability and activity of lacosamide in patients with ...
12036945 - Inactivation of e2f1 enhances tumorigenesis in a myc transgenic model.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-8
Journal Detail:
Title:  International journal of cancer. Journal international du cancer     Volume:  -     ISSN:  1097-0215     ISO Abbreviation:  Int. J. Cancer     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0042124     Medline TA:  Int J Cancer     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 UICC.
Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Molecular pathogenesis of infections caused by Moraxella catarrhalis in children.
Next Document:  From Osmium Hydrido Vinylidene to Osmacycles: The Key Role of Osmabutadiene Intermediates.